SEATTLE – Although previous research has linked alcohol consumption to an increased risk of developing breast cancer, a new study has found that drinking before and after diagnosis does not impact survival from the disease. In fact, a modest survival benefit was found in women who were moderate drinkers before and after diagnosis due to a reduced risk of dying from cardiovascular disease, a major cause of mortality among breast cancer survivors.
The study results will be published in the April 8 edition of the Journal of Clinical Oncology. Polly Newcomb, Ph.D., a member of the Public Health Sciences Division and head of the Cancer Prevention Program at Fred Hutchinson Cancer Research Center, led the study.
"Our findings should be reassuring to women who have breast cancer because their past experience consuming alcohol will not impact their survival after diagnosis," said Newcomb. "This study also provides additional support for the beneficial effect of moderate alcohol consumption with respect to cardiovascular disease."
The study was based on data from almost 23,000 women who participated in the Collaborative Breast Cancer Study, a National Cancer Institute-sponsored, multi-site, population-based study of risk factors for breast cancer. The study began in 1988 and was conducted in New Hampshire, Massachusetts and Wisconsin. In a smaller follow-up study between 1998 and 2001, about 5,000 participants were sent a follow-up questionnaire about their alcohol consumption habits after diagnosis.
Among study participants with a history of breast cancer, the authors found that the amount and type of alcohol a woman reported consuming in the years before her diagnosis was not associated with her likelihood from dying from breast cancer. However, the authors also found that those who consumed a moderate level of alcohol (three to six drinks per week) in the years before their cancer diagnosis were 15 percent less likely to die from cardiovascular disease than non-drinkers. Moderate wine consumption in particular was associated with a lower risk of cardiovascular disease mortality, while no such benefit was evident for consumption of beer or spirits, or for heavier levels of alcohol consumption.
Similar patterns were evident when considering reported alcohol consumption after breast cancer diagnosis. The amount and type of alcohol a woman consumed after diagnosis did not appear to be associated with survival of breast cancer, but those who consumed alcohol in moderation experienced a 39- to 50-percent lower mortality rate from cardiovascular disease.
What could account for the difference in alcohol's impact on developing breast cancer risk and on survival from the disease? "It could be that the kind of breast cancer that is more likely to be diagnosed among women who drink may be more responsive to hormone-reduction therapies," Newcomb said. Alcohol consumption is believed to influence breast cancer risk through increases in estrogen production in both pre- and post-menopausal women.
Funding for the study was provided by grants from the National Cancer Institute and Komen for the Cure. Co-authors included researchers from the University of Wisconsin Paul B. Carbone Comprehensive Cancer Center, Wageningen University in the Netherlands, H. Lee Moffitt Cancer Center, Norris Cotton Cancer Center, the University of North Carolina Lineberger Cancer Center and Research Institute, and Harvard Medical School and Brigham and Women's Hospital.
Editor's note: Please contact Dean Forbes in Fred Hutch media relations to request interviews with Newcomb. Please contact the journal - mediateam@asco.org – to obtain an embargoed copy of the Journal of Clinical Oncology paper, "Alcohol Consumption Before and After Breast Cancer Diagnosis: Associations with Survival From Breast Cancer; Cardiovascular Disease and Other Causes."
About Fred Hutchinson Cancer Research Center
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit http://www.fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.
CONTACT
Dean Forbes
Journal
Journal of Clinical Oncology